Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients 2020, 12(3):747.

• https://www.mdpi.com/2072-6643/12/3/747

Cacabelos R, Carrera I, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, Rodríguez S, Alcaraz M, Tellado I, Cacabelos N, Pego R, Carril JC. Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinson’s Disease. Planta Med.  2019, 85(17):1351-1362.

• https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1013-7686

Teijido O.; Cacabelos R. Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases. Int. J. Mol. Sci. 2018, 19, 3199.

• https://www.mdpi.com/1422-0067/19/10/3199

Carrera I, Fernandez-Novoa L, Sampedro C, Tarasov VV, Aliev G, Cacabelos R. Dopaminergic Neuroprotection with AtreMorine in Parkinson´s Disease. Current Medicinal Chemistry 2018, 25: 5372. 

• https://www.eurekaselect.com/161141/article

Cacabelos R, Lombardi VRM, Fernández-Novoa l, Carrera I, Cacabelos P, Corzo L, Carril JC, Teijido O. Chapter 6 – Basic and Clinical Studies With Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. Volume 59, 2018, Pages 195-225.

• https://www.sciencedirect.com/science/article/pii/B9780444641793000062

Cacabelos R, Carril JC, Cacabelos P, Fernández-Novoa L, Arun M. Pharmacogenetics of Neurodegenerative disorders. Internal Medicine Review 2017, 3. 10.18103/imr.v3i6.472.

• https://internalmedicinereview.org/index.php/imr/article/view/472

Cacabelos R. Parkinson’s Disease: From Pathogenesis to Pharmacogenomics. Int. J. Mol. Sci. 2017, 18(3), 551.

• https://www.mdpi.com/1422-0067/18/3/551

Cacabelos R, Carril JC, Teijido O. Chapter 5. Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. Anti-aging Drugs: From Basic Research to Clinical Practice 2017, 75-141.

• https://pubs.rsc.org/en/content/chapter/bk9781782624356-00075/978-1-78262-435-6

Romero A, Parada E, González‐Lafuente L, Farré‐Alins V, Ramos E, Cacabelos R, Egea J. Neuroprotective effects of E‐PodoFavalin‐15999 (Atremorine®). CNS Neurosci Ther 2017, 23:450‐452.

• https://onlinelibrary.wiley.com/doi/full/10.1111/cns.12693

Carrera I, Fernandez-Novoa L, Sampedro C, Cacabelos R. Neuroprotective Effect of AtreMorine in an Experimental Model of Parkinson’s disease. Current Pharmaceutical Design 2017, Vol 23 (18): 2673-2684(12).

• https://www.ingentaconnect.com/contentone/ben/cpd/2017/00000023/00000018/art00011#expand/collapse

Cacabelos R. Novel Biotechnological Products from Natural Sources: Nutri/Pharmacogenomic Component. J Nutr Food Sci 2016, 6:6.

• https://www.longdom.org/open-access/novel-biotechnological-products-from-natural-sources-nutri-pharmacogenomic-component-2155-9600-1000e135.pdf

Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Alcaraz M, Nebril L, Cacabelos P, Fraile C, Carrera I and Carril JC. E-PodoFavalin-15999 (Atremorine®)-Induced Neurotransmitter and Hormonal Response in Parkinson’s disease. J Exp Res Pharm 2016, 1(1):1-12.

• https://www.xiahepublishing.com/ArticleFullText.aspx?sid=2&jid=3&id=10.14218%2FJERP.2016.00031

Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Alcaraz M, Nebril L, Cacabelos P, Fraile C, Carrera I and Carril JC. E-PodoFavalin-15999 (Atremorine®)-Induced Dopamine Response in Parkinson’s disease: Pharmacogenetics-Related Effects. Gen Med Pharm 2016, 1(1):1‐26.

• https://www.scitcentral.com/article/20/75/E-PodoFavalin-15999-(Atremorine%C2%AE)-Induced-Dopamine-Response-in-Parkinson%E2%80%99s-Disease:-Pharmacogenetics-Related-Effects